PACMA 31 is primarily used in research settings to study its potential as an anticancer agent. It functions by inhibiting protein disulfide isomerase (PDI), an enzyme that plays a critical role in protein folding and cancer cell survival. By targeting PDI, PACMA 31 disrupts the proper folding of proteins in cancer cells, leading to cellular stress and apoptosis. This mechanism makes it a promising candidate for the development of novel cancer therapies, particularly for tumors that rely heavily on PDI activity for growth and survival. Researchers are also exploring its use in combination with other anticancer drugs to enhance therapeutic efficacy and overcome drug resistance.